Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors-Reference-Cited by-同舟云学术

Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors

Published:2021-04 Issue:4 Volume:2 Page:100157
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Gibson Amanda J.W.,Box Adrian,Dean Michelle L.,Elegbede Anifat A.,Hao Desiree,Sangha Randeep,Bebb D. Gwyn

Funder

Pfizer Canada

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference45 articles.

1. Real-world use and outcomes of ALK-positive crizotinib treated metastatic NSCLC in US community oncology practice: a retrospective observational study;Reynolds;J Clin Med,2018

2. Clinical data from the real world: efficacy of crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases;Xing;Oncotarget,2016

3. Research Electronic Data Capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support;Harris;J Biomed Inform,2009

4. The REDCap consortium: building an international community of software partners;Harris;J Biomed Inform,2019

5. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of TGFBR3 in the Development of Lung Cancer;Protein & Peptide Letters;2024-07

2. Lung cancer patients with anaplastic lymphoma kinase rearrangement lose affiliation with labor market at diagnosis;Lung Cancer Management;2024-03-13

3. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update;Tumor Biology;2023-10-12

4. Clinical outcomes of ALK + non-small cell lung cancer in Denmark;Acta Oncologica;2023-10-10

5. Diverse Resistant Mechanisms Identified Using Serial Next-Generation Sequencing in a Patient With ALK-Rearranged Metastatic Lung Adenocarcinoma: A Case Report;JTO Clinical and Research Reports;2023-06